Latest:
Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL
Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jens Bedke, MD
Jens Bedke, MD, is a senior consultant in the Department of Urology & Transplantation Surgery at the Eva Mayr-Stihl Cancer Center Stuttgart, Klinikum Stuttgart in Germany.
Latest:
Dr Bedke on Advice for Using Enfortumab Vedotin/Pembrolizumab in Previously Untreated Advanced Urothelial Carcinoma
Jens Bedke, MD, discusses considerations for using enfortumab vedotin plus pembrolizumab in the frontline setting for advanced urothelial carcinoma.
Rachel Riechelmann, MD, PhD
Rachel Riechelmann, MD, PhD, is a medical oncologist, postgraduate professor, and clinical scientist specialized in neuroendocrine tumors (NET) and colorectal/anal cancers
Latest:
Dr Riechelmann on the Management of Refractory Carcinoid Syndrome in Functional GI NETs
Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.
Koral Shah, MD
Koral Shah, MD, is a fellow in Hematology & Medical Oncology at City of Hope in Duarte, California.
Latest:
Dr Shah on Disparities in Worldwide Bladder Cancer Trial Availability
Koral Shah, MD, details the rationale of evaluating worldwide disparities in bladder cancer clinical trial availability.
Shipra Gandhi, MD
Latest:
Insights From SABCS 2024 and Future Directions in Breast Cancer
Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.
Hiromichi Shirasu, MD
Latest:
Dr. Shirasu on the Clinical Implications of ctDNA in CRC
Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.
Kerry Savage, MD, MSc
Kerry Savage, MD, MSc, is a medical oncologist at BC Cancer and a professor of medicine at the University of British Columbia.
Latest:
Decoding T-Cell Lymphomas: An Approach to Diagnosis & Treatment
Kerry Savage, MD, MSc, and Neha Mehta-Shah, MD, discuss approaches to diagnosing and treating T-cell lymphomas.
David M. Loeb, MD, PhD
David M. Loeb, MD, PhD, is chief of the Division of Pediatric Hematology, Oncology, and Cellular Therapy Children’s Hospital at Montefiore. He is also a professor in the Department of Pediatrics (Pediatric Hematology-Oncology) and Department of Development & Molecular Biology at Albert Einstein College of Medicine, and a member of Montefiore Einstein Comprehensive Cancer Center in Bronx, NY.
Latest:
From the Lab to the Clinic: Exploring DFMO’s Potential to Prevent Metastatic Disease in Children With Osteosarcoma and Ewing Sarcoma
DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.
Pietro Scilipoti, MD
Pietro Scilipoti, MD, is a urologist at IRCCS San Raffaele Hospital in Italy.
Latest:
Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies
Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.